US2023141310A1PendingUtilityA1
Human gut microbiome-derived biosynthetic enzymes for production of fatty acid amides
Assignee: MASSACHUSETTS INST TECHNOLOGYPriority: Mar 8, 2019Filed: Jul 12, 2022Published: May 11, 2023
Est. expiryMar 8, 2039(~12.6 yrs left)· nominal 20-yr term from priority
C12Y 602/0102C12P 13/02C12Y 204/00C12Y 207/08007C07K 14/33C12Y 203/01C12Y 203/01041C12Y 207/07006
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein, in some embodiments, are vectors encoding biosynthetic enzymes from gut microbiome-derived bacterium (e.g., Clostridia enzymes), engineered cells comprising the vectors, and methods of using biosynthetic enzymes from gut microbiome-derived bacterium (e.g., Clostridia enzymes) to produce fatty acid amides.
Claims
exact text as granted — not AI-modified1 - 38 . (canceled)
39 . A vector for the production of fatty acid amides, comprising
genes, wherein each of the genes is under the control of a regulatory element, wherein each of the genes is derived from a gut microbiome-derived bacterium, and wherein the genes encode at least a fatty acyl transferase, an acyl carrier protein, and a fatty acyl-ACP synthetase.
40 . The vector of claim 39 , wherein the regulatory element is an inducible promoter.
41 . The vector of claim 39 , wherein the regulatory element is a constitutive promoter.
42 . The vector of claim 39 , wherein the regulatory element is a repressible promoter.
43 . The vector of claim 39 , wherein the regulatory element comprises a T7 promoter.
44 . The vector of claim 43 , wherein the vector further encodes a T7 RNA polymerase.
45 . The vector of claim 39 , further comprising a ribosomal binding site.
46 . The vector of claim 39 , wherein the genes are codon-optimized.
47 . The vector of claim 39 , wherein the genes are open reading frames.
48 . The vector of claim 39 , wherein the genes are codon-optimized for production in E. coli .
49 . The vector of claim 39 , wherein the gut microbiome-derived bacterium is from Clostridia.
50 . The vector of claim 39 , wherein the genes also encode a hydrolase.
51 . The vector of claim 39 , wherein the genes also encode a lipid transfer protein.
52 . The vector of claim 39 , wherein the genes also encode a glycosyltransferase.
53 . The vector of claim 39 , wherein the genes encode Sfp 4′-phosphopantetheinyl transferase.
54 . The vector of claim 39 , wherein the genes are in a single operon.
55 - 74 . (canceled)
75 . An engineered cell comprising the vector of claim 39 .
76 . A method of producing fatty acid amides, the method comprising:
contacting a composition, comprising one or more exogenous fatty acids and one or more amines, with a set of biosynthetic enzymes which are human gut microbiome-derived clostridia biosynthetic enzymes in an effective amount to produce a fatty acid amide, wherein the set of biosynthetic enzymes comprise a fatty acyl transferase, an acyl carrier protein, and a fatty acyl-ACP synthetase.Join the waitlist — get patent alerts
Track US2023141310A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.